Investor predicts huge Wegovy potential in US
The Novo Nordisk stock is setting one record after the other, a development driven by investors’ high sales expectations for the Danish drugmaker’s very popular obesity drug, Wegovy (semaglutide).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.